$EVFM – Evofem Biosciences, Inc., promotional campaign starting May 17, 2022 @ 1:12 PM CST

on May 17, 2022 Stock Promotion Tracking and Tags: , , , , , , , , , with 0 comments

Summary

Start time:
1:12 PM
Start date:
May 17, 2022
Symbol:
EVFM
Company:
Evofem Biosciences, Inc.
Stock promoter:
"OTC Stock Review"
Stock promoter rank:
17 out of 22
Promoter score:
8.0
Campaign ID:
37243

Evofem Biosciences, Inc.

Market capitalization:
$80,510,049
(as of August 30, 2021)
Website:
Outstanding shares:
102,835,674
(as of April 30, 2021)

Stock Promoter Performance

The following charts displays the first day results for campaigns by "OTC Stock Review". Results are taken from a total of 18 stock promotions by this stock promoter that have been tracked by OTC Dynamics.
43% closed down

40% closed up

16% had no net effect

Last 3 Stock Promotions By "OTC Stock Review"

Symbol Company Start Date Close Change
SLDX STELLA DIAGNOSTICS INC. April 8, 2022 1.04 -13%
CRDV COMMUNITY REDEVELOPMENT INC. April 6, 2022 2.50 25%
SLDX STELLA DIAGNOSTICS INC. February 10, 2022 1.00 -9%

EVFM Promotional Newsletter

The following is a newsletter released by "OTC Stock Review" promoting Evofem Biosciences, Inc.

Caution

The following newsletter has not been verified for accuracy or completeness.

OTC Stock Review Award Winning Small Cap Stock Picks Since 2004

Evofem Biosciences

Dear

Take a look at Evofem Biosciences, Inc. NASDAQ EVFM. Evofem's first FDA-approved product is Phexxi, a hormone-free, on-demand prescription contraceptive vaginal gel method of birth control used for the prevention of pregnancy. Phexxi comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Like I said, it is FDA approved and currently on the market.

I have talked to Evofem Bioscience CEO, Saundra Pelletier. I am not easily excitable about a company, but I was very excited about EVFM. Here is who is changing women's health forever

After I talked to her, I bought 5,000 shares this morning at $1.06 and another 5,000 at $1.10. I'm going to buy more after you buy some, and I think we will all make a lot of money.

Company website
Phexxi website

Five reasons to buy this stock right now

Evofem increased Phexxi net product sales 19% to $4.3 million for the first quarter of 2022 vs. fourth quarter 2021.
Evofem reduced its selling and marketing costs by 49% and its total operating expense by 19%.
Huge Short position
Great news coming from the Affordable Care Act
Another vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women coming soon It has been Fast Tracked by the FDA

Evofem has been hammered by the shorts, who will probably be forced to cover. Evofem did a 1-for-15 reverse stock split on Thursday, May 5, 2022, which left the company with about 12.5 million shares outstanding at roughly $1.10 a share. So, yep, thats a market cap of $14 million

Here's where it gets good Evofem posted $8.24 million in product sales for fiscal 2021. Not only did Evofem, with its ridiculous $14 million market cap, do $8.4 million in sales for 2021, Evovem did You know why this is a big deal, and why it gets me excited about EVFM Because, according to So, EVFM should have a market cap of around $65 million. With 12.5 million shares out, that's around $5 per share If that's not enough to get your small-cap stock infused blood pumping,

I struggled with advanced math in college, but I know how to multiply. $35 million in sales times 5.47 for the average Biotechnology Pharmaceutical Industry stock. According to my calculator, it comes out to more than a $190 million market cap. You divide that $190 million market cap by 12.5 million shares and we are looking at a $15 stock price Let's say I'm half right. Maybe even figure that, like most biopharma companies, Evofem issues some more shares to raise some cash to execute on its business plan. So, say I'm 25% right. If I'm 25% right, and the stock goes to $3.75 from $1.10, you will probably be happy with a triple. With this crazy market we're in, some of you would probably be happy to buy a stock that trades higher

Phexxi - The First and Only Hormone-Free, On-Demand Prescription Contraceptive Vaginal Gel

In the interest of getting you timely information, this is copied directly from . I encourage you to do some more research. Phexxi vaginal gel provides women an in-the-moment contraceptive that can be easily applied 0-60 minutes before each act of intercourse and works by maintaining the baseline vaginal pH environment.

Baseline vaginal pH levels can range from 3.5 to 4.5. When semen enters the vagina, it raises the vaginas pH level, which allows sperm to be mobile and swim up the reproductive canal. Phexxi works to keep vaginal pH in the baseline range of 3.5 to 4.5, which lowers sperm mobility, lowering the chance of sperm reaching the egg.

Women should not have to rely on a daily ritual, their partner, an invasive procedure, or an injection from their physician to protect themselves from unwanted pregnancy. Many women seek a safe, FDA-approved localized method of birth control that does not require the introduction of hormones into their bodies.

Because Phexxi is a non-hormonal birth control, it is not associated with side effects like depression, mood swings and irritability. Taking hormones may not be right for some women, especially for those with certain medical conditions including clotting disorders and most cancers, limiting their birth control options.

Phexxi provides a hormone-free contraceptive option for women who cannot or do not want to use a hormonal contraceptive as their birth control method. Phexxi is the hormone-free birth control women have been waiting for.

Proven Safe and Effective

Phexxi is 93% effective at preventing pregnancy when used as directed by a healthcare provider.

Phexxi is 86% effective with typical use typical use includes women who may not have correctly followed the Instructions for Use during the clinical trial.

2011 Affordable Care Act Free Birth Control

This is not being enforced, but it will be on January1, 2023. This is going to be a big win for EVFM

In 2011, President Obama signed the birth control mandate into law as part of the Affordable Care Act ACA. Since the birth control mandate came into effect, the number of women with out-of-pocket expenses towards contraceptives dropped from 21% to 3%. What most people understand about the mandate is that .

Before the birth control mandate passed, women were required to pay out-of-pocket costs for birth control alongside their health insurance premium and yearly deductible. After the birth control mandate was signed into law, women in the United States no longer had to pay those out-of-pocket costs, as the ACA required insurance companies to cover contraceptive methods and counseling even if they hadnt met their deductibles.

Roe vs. Wade

The , according to a leaked initial draft majority opinion written by Justice Samuel Alito. Maybe it's true, maybe it's not If it is true, FDA-approved contraceptives, like Phexxi, are going to be in big demand.

Chlamydia amd Gonorrhoeae

Evofem is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofems pipeline includes programs developing Phexxi for the prevention of two common STIs and EVO200 to reduce recurrent Bacterial Vaginosis BV.

Every day, more than 1 million new cases of sexually transmitted infections STIs are acquired worldwide among people aged 15-49 years.4Every sexually active woman, no matter what form of contraception she is using, is potentially at risk to contract an STI.

In the United States, the CDC estimates that 4.0 million and 1.6 million new cases of chlamydia and gonorrhea, respectively, occurred in 2018 alone.6 The number of reported cases is lower than the estimated total number because infected people are often unaware of, and do not seek treatment for, their infections. Almost 60% of women infected with chlamydia have no symptoms.7

Chlamydia and gonorrhea have been reported to be responsible for one-third to half of pelvic inflammatory disease PID cases. PID can cause serious, long-term problems including infertility, ectopic pregnancy, and chronic pelvic pain.8

In 2020, Evofem initiated EVOGUARD, a confirmatory Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 the investigational name for Phexxi for the prevention of urogenital transmission of chlamydia and gonorrhea in women. Top-line study results are expected in the second half of 2022.

The U.S. Food and Drug Administration granted EVO100 Phexxi Fast Track designation for the prevention of both chlamydia and gonorrhea. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.

Additionally, the FDA has awarded EVO100 Phexxi Qualified Infectious Disease Product QIDP designation for the prevention of both chlamydia and gonorrhea in women. A drug that receives QIDP designation may qualify for an additional five years of marketing exclusivity.

EVOGUARD builds on the positive, statistically significant results of the Companys AMPREVENCE Phase 2b clinical trial. This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo.5 The AMPREVENCE manuscript was published in the prestigious peer-reviewed journal American Journal of Obstetrics and Gynecology in 2021.

Assuming FDA approval for these potential new indications, Phexxi is expected to be the first prescription product approved to address this critical large unmet medical need.

OTC Stock Review is not registered as an Investment Advisor or a BrokerDealer. The information in this newsletter is not an offer to buy or sell securities of the companies profiled. Information is for informative purposes, not intended as advice for investment and is subject to change without notice. OTC Stock Review has been compensated fifty thousand dollars to perform investor relations services for evfm. Officers and directors of OTC Stock Review hold a long equity position in evfm and may from time to time trade in these securities for their own accounts. Information on each company is from public releases and can not be guaranteed by OTC Stock Review. Companies profiled herein may carry a high investment risk readers should carefully review profiled companies thoroughly with their investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled Companies and reflects the opinion of the author. Readers should obtain copies of the profiled Companys periodic reports filed with United States Securities and Exchange Commission, generally available at or .

If you no longer wish to receive these emails, please reply to this message with Unsubscribe in the subject line or simply click on the following link

OTC Stock Review
3455 Peachtree Rd. N.E.
5th Floor
Atlanta, Georgia 30328
US

the marketing policy.

Get Every Penny Stock Alert!

OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!

Sign up today!

Note

OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.

The information on this page is not a recommendation to buy or sell securities.